We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

46 hedge funds and large institutions have $72.8M invested in Gyre Therapeutics in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

822% more call options, than puts

Call options by funds: $83K | Put options by funds: $9K

3% less capital invested

Capital invested by funds: $75.1M → $72.8M (-$2.31M)

6% less funds holding

Funds holding: 49 → 46 (-3)

33% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 12

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
46
Holders Change
-3
Holders Change %
-6.12%
% of All Funds
1.24%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
4
Increased
8
Reduced
12
Closed
7
Calls
$83K
Puts
$9K
Net Calls
+$74K
Net Calls Change
-$207K

Top Buyers

1
DCM
DG Capital Management
New York
+$4.08M
2
ACA
Avoro Capital Advisors
New York
+$309K
3
Renaissance Technologies
Renaissance Technologies
New York
+$196K
4
AA
Ancora Advisors
Ohio
+$126K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$126K

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.24M
2
BCM
Bridgeway Capital Management
Texas
-$1.23M
3
Deutsche Bank
Deutsche Bank
Germany
-$198K
4
PPA
Parametric Portfolio Associates
Washington
-$116K
5
NCCM
Nine Chapters Capital Management
New Jersey
-$55K
Name Holding Trade Value Shares
Change 		Change in
Stake
SIM
26
Spark Investment Management
New York
$181K -$8.02K -4 -5%
AA
27
Ancora Advisors
Ohio
$139K +$126K +63 New
WMSA
28
Weiss Multi-Strategy Advisers
New York
$130K – – –
Northern Trust
29
Northern Trust
Illinois
$128K -$36.1K -18 -24%
Bank of America
30
Bank of America
North Carolina
$110K +$6.01K +3 +6%
OA
31
Oak Associates
Ohio
$107K – – –
PAM
32
Panagora Asset Management
Massachusetts
$56K – – –
State Street
33
State Street
Massachusetts
$51K -$12K -6 -21%
OAM
34
Oxford Asset Management
United Kingdom
$37K -$40.1K -20 -54%
PP
35
PDT Partners
New York
$28K – – –
ACA
36
Apis Capital Advisors
New York
$28K +$26.1K +13 New
NFA
37
Nationwide Fund Advisors
Ohio
$26K – – –
BIM
38
BlackRock Investment Management
Delaware
$13K -$2K -1 -14%
MA
39
MUFG Americas
New York
$11K – – –
Walleye Trading
40
Walleye Trading
New York
$6K +$6.01K +3 New
GT
41
Glenmede Trust
Pennsylvania
$1K – – –
JAM
42
Jolley Asset Management
North Carolina
$1K – – –
LTFS
43
Ladenburg Thalmann Financial Services
Florida
$1K – – –
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$1K – – –
SAM
45
Shamrock Asset Management
Texas
$1K – – –
Simplex Trading
46
Simplex Trading
Illinois
$1K – – –
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2 – – –
BCM
48
Bridgeway Capital Management
Texas
– -$1.23M -524 Closed
PPA
49
Parametric Portfolio Associates
Washington
– -$116K -50 Closed
NCCM
50
Nine Chapters Capital Management
New Jersey
– -$55K -24 Closed
1
2
3

GYRE Hedge Fund Activity: Q2 2015 in Review

46 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2015, worth a combined $72.8M — down 3.1% from $75.1M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of GYRE and 4 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 8 added.

The largest buyer was DG Capital Management, opening a new position worth an estimated $4.08M. The largest seller was Vanguard Group, cutting an estimated $1.24M.

  • 46 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2015, down from 49 in Q1 2015.
  • Funds reported $72.8M of Gyre Therapeutics stock for Q2 2015, down 3.1% quarter-over-quarter.
  • 4 funds opened new Gyre Therapeutics positions in Q2 2015 and 7 closed out, a net change of -3 holders.
  • The largest Gyre Therapeutics buyer in Q2 2015 was DG Capital Management, an estimated $4.08M added.
  • The largest Gyre Therapeutics seller in Q2 2015 was Vanguard Group, an estimated $1.24M sold.

Based on aggregated 13F filings for Q2 2015.